Leerink Partnrs Has Negative Outlook of ELAN Q2 Earnings

Elanco Animal Health Incorporated (NYSE:ELAN) – Stock analysts at Leerink Partnrs dropped their Q2 2025 earnings per share estimates for shares of Elanco Animal Health in a research report issued to clients and investors on Wednesday, May 7th. Leerink Partnrs analyst D. Clark now anticipates that the company will earn $0.20 per share for the quarter, down from their prior estimate of $0.26. The consensus estimate for Elanco Animal Health’s current full-year earnings is $0.91 per share. Leerink Partnrs also issued estimates for Elanco Animal Health’s FY2027 earnings at $1.07 EPS and FY2028 earnings at $1.24 EPS.

Several other equities research analysts have also issued reports on the company. Morgan Stanley lowered their price objective on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 26th. UBS Group lowered their price target on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. Barclays cut their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. Piper Sandler lowered their target price on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating for the company in a report on Thursday, March 6th. Finally, Stifel Nicolaus lifted their price target on shares of Elanco Animal Health from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $15.00.

Elanco Animal Health Stock Down 2.1 %

Shares of NYSE:ELAN opened at $12.02 on Friday. The company has a market cap of $5.97 billion, a price-to-earnings ratio of 30.05, a PEG ratio of 2.50 and a beta of 1.49. Elanco Animal Health has a 12 month low of $8.02 and a 12 month high of $18.80. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. The company has a 50-day moving average price of $9.89 and a 200 day moving average price of $11.43.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.06. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the prior year, the firm earned $0.34 earnings per share. Elanco Animal Health’s revenue was down 1.0% on a year-over-year basis.

Institutional Investors Weigh In On Elanco Animal Health

A number of institutional investors and hedge funds have recently bought and sold shares of ELAN. Allworth Financial LP increased its stake in shares of Elanco Animal Health by 791.7% during the first quarter. Allworth Financial LP now owns 2,354 shares of the company’s stock valued at $25,000 after buying an additional 2,090 shares during the period. Wilmington Savings Fund Society FSB bought a new position in shares of Elanco Animal Health in the 3rd quarter worth $35,000. CoreCap Advisors LLC bought a new position in shares of Elanco Animal Health in the 4th quarter worth $29,000. Parallel Advisors LLC lifted its stake in shares of Elanco Animal Health by 92.2% during the 1st quarter. Parallel Advisors LLC now owns 3,860 shares of the company’s stock worth $41,000 after purchasing an additional 1,852 shares during the last quarter. Finally, NBC Securities Inc. bought a new stake in Elanco Animal Health during the first quarter valued at about $40,000. 97.48% of the stock is owned by institutional investors.

Insider Activity

In other news, Director Lawrence Erik Kurzius purchased 10,000 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was purchased at an average price of $10.90 per share, for a total transaction of $109,000.00. Following the completion of the acquisition, the director now owns 101,459 shares of the company’s stock, valued at approximately $1,105,903.10. This trade represents a 10.93 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.89% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.